Summary

Market Size & Trends

The Middle East hereditary cancer testing market size was estimated at USD 66.25 million in 2024 and is projected to reach USD 169.10 million by 2033, growing at a CAGR of 11.28% from 2025 to 2033. The market is expanding rapidly, driven by high cancer prevalence, consanguinity, and national precision medicine initiatives. In the UAE, partnerships such as Viafet Genomics with Euformatics are strengthening NGS-based hereditary cancer testing, supported by the National Cancer Control Plan. Qatar, through the Qatar Genome Programme and NCCCR, has pioneered BRCA testing and large-scale genome sequencing, positioning itself as a leader in precision oncology. Kuwait aligns with global hereditary cancer rates (10%) and is advancing genetic services, IVF success, and early cancer detection through KCCC-led initiatives.

The Middle East hereditary cancer testing market is evolving rapidly, driven by high cancer incidence rates, unique demographic structures, and strong government-led precision medicine initiatives. Countries such as the UAE, Qatar, and Kuwait are spearheading regional adoption by embedding hereditary testing into cancer control frameworks, expanding laboratory capabilities, and integrating genomics into public health programs. Collectively, these factors are positioning the region as a fast-growing market for hereditary and predictive oncology diagnostics.

The UAE has emerged as a frontrunner in precision oncology. In 2021, the country reported 5,830 new cancer cases, with a crude incidence rate of 60.5 per 100,000 and an age-standardized rate of 107.8 per 100,000. Breast cancer was the leading malignancy, accounting for 20.3% of all cancers, followed by thyroid (10.6%) and colorectal cancers (9.5%). Emiratis represented 25.6% of cases, while expatriates-who form the majority population-accounted for 74.4%, underscoring the need for inclusive testing strategies. Despite clear hereditary risk, screening uptake remains low-only around 25% for both breast and colorectal cancer. This gap creates strong potential for hereditary testing to complement screening and identify high-risk individuals earlier. Hospitals are adopting NGS-based multi-gene panels, BRCA1/2, PALB2, and Lynch syndrome testing, as well as liquid biopsies. Policy frameworks such as the National Cancer Control Plan (2022-2026) and updated National Cancer Screening Guidelines mandate structured programs, integrate molecular diagnostics, and expand insurance coverage.

The UAE’s ecosystem is also being shaped by private-sector innovation and global partnerships. A notable example is the 2022 collaboration between Viafet Genomics Laboratory in Dubai and Euformatics, aimed at expanding clinical genetics services across the Gulf. Viafet has deployed Euformatics’ OmnomicsNGS bioinformatics platform in its data center to support a wide range of next-generation sequencing (NGS) applications, from whole exome analysis to carrier screening and hereditary cancer testing. The flexibility of the platform to manage both single-patient and multi-patient pipelines, combined with integrated quality control and validation, strengthens confidence in clinical-grade genetic data. By tailoring reporting frameworks and optimizing workflows, the partnership has enhanced Viafet’s capacity to deliver high-quality hereditary and cancer genomics services in the UAE. Together with national-level precision medicine policies, these advancements underscore why the UAE is set to grow at a double-digit CA
GR, positioning it as a cornerstone of precision oncology in the region.

Qatar represents one of the region’s most advanced hereditary cancer testing ecosystems, shaped by its high consanguinity rate of nearly 55%, large family structures, and strong state-backed genomics programs. Breast cancer accounts for 36% of female cancers, with early-onset disease prevalent among Qatari women due to BRCA1/2 mutations and founder effects. The Hereditary Breast and Ovarian Cancer and High-Risk Clinic, launched in 2013 at the National Center for Cancer Care and Research (NCCCR), pioneered regional hereditary testing. By 2016, it had evaluated 697 patients, with 38% testing BRCA-positive, and such cases were strongly linked to young-onset, triple-negative breast cancer. In 2015, in-house CAP-accredited BRCA testing at Hamad Medical Corporation removed cost barriers and increased uptake. National-scale initiatives such as the Qatar Genome Programme and Qatar Biobank have already sequenced more than 29,000 genomes, targeting 100,000 by 2025, and developed tools such as QChipPMv2 for variant detection. Coupled with translational research at Sidra Medicine and QBRI, Qatar has built a globally competitive infrastructure. Furthermore, the launch of a genetic counseling master’s program in 2018 ensures culturally sensitive expertise, positioning Qatar as both a domestic leader and regional model for hereditary cancer testing and precision oncology.

Middle East Hereditary Cancer Testing Market Report Segmentation

This report forecasts revenue growth at regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For the purpose of this study, Grand View Research has segmented the Middle East hereditary cancer testing market report on the basis of cancer, test type, technology, end use, and country:

• Cancer Outlook (Revenue, USD Million, 2021 - 2033)
• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Cervical Cancer
• Ovarian Cancer
• Prostate Cancer
• Stomach/Gastric Cancer
• Melanoma
• Sarcoma
• Uterine Cancer
• Pancreatic Cancer
• Others
• Technology Outlook (Revenue, USD Million, 2021 - 2033)
• Cytogenetic
• Biochemical
• Molecular Testing
• Test Type Outlook (Revenue, USD Million, 2021 - 2033)
• Predictive Testing
• Diagnostic Testing
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Diagnostic Centers
• Hospitals
• Clinics
• Country Outlook (Revenue in USD Million, 2021 - 2033)
• Middle East
o UAE
o Kuwait
o Oman
o Qatar

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Cancer
1.2.2. Technology
1.2.3. Regional scope
1.2.4. Estimates and forecasts timeline.
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Cancer outlook
2.2.2. Technology outlook
2.2.3. Test Type outlook
2.2.4. End Use outlook
2.2.5. Regional outlook
2.3. Competitive Insights
Chapter 3. ME Hereditary Cancer Testing Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook.
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Technological advancements of genetic testing in cancer detection
3.2.1.2. Integration with precision medicine
3.2.1.3. Growing awareness through public and government initiatives
3.2.1.4. Rising prevalence of cancer
3.2.2. Market restraint analysis
3.2.2.1. High costs and limited insurance coverage
3.3. ME Hereditary Cancer Testing Market Analysis Tools
3.3.1. Industry Analysis – Porter’s
3.3.2. PESTEL Analysis
Chapter 4. ME Hereditary Cancer Testing Market: Cancer Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. ME Hereditary Cancer Testing Market: Cancer Movement Analysis
4.3. ME Hereditary Cancer Testing Market Size & Trend Analysis, by cancer, 2021 to 2033 (USD Million)
4.4. ME Hereditary Cancer Testing Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5. Lung Cancer
4.5.1. Lung Cancer Market estimates and forecasts 2021 to 2033 (USD Million)
4.6. Breast Cancer
4.6.1. Breast Cancer Market estimates and forecasts 2021 to 2033 (USD Million)
4.7. Colorectal Cancer
4.7.1. Colorectal Cancer Market estimates and forecasts 2021 to 2033 (USD Million)
4.8. Cervical Cancer
4.8.1. Cervical Cancer Market estimates and forecasts 2021 to 2033 (USD Million)
4.9. Ovarian Cancer
4.9.1. Ovarian Cancer Market estimates and forecasts 2021 to 2033 (USD Million)
4.10. Prostate Cancer
4.10.1. Prostate Cancer Market estimates and forecasts 2021 to 2033 (USD Million)
4.11. Stomach/Gastric Cancer
4.11.1. Stomach/Gastric Cancer Market estimates and forecasts 2021 to 2033 (USD Million)
4.12. Melanoma
4.12.1. Melanoma Market estimates and forecasts 2021 to 2033 (USD Million)
4.13. Sarcoma
4.13.1. Sarcoma Market estimates and forecasts 2021 to 2033 (USD Million)
4.14. Uterine Cancer
4.14.1. Uterine Cancer Market estimates and forecasts 2021 to 2033 (USD Million)
4.15. Pancreatic Cancer
4.15.1. Pancreatic Cancer Market estimates and forecasts 2021 to 2033 (USD Million)
4.16. Others
4.16.1. Others Market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 5. ME Hereditary Cancer Testing Market: Technology Estimates & Trend Analysis
5.1. Technology Market Share, 2024 & 2033
5.2. Segment Dashboard
5.3. ME Hereditary Cancer Testing Market by Technology Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
5.5. Cytogenetic
5.5.1. Cytogenetic Market estimates and forecasts 2021 to 2033 (USD Million)
5.6. Biochemical
5.6.1. Biochemical Market estimates and forecasts 2021 to 2033 (USD Million)
5.7. Molecular Testing
5.7.1. Molecular Testing Market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 6. ME Hereditary Cancer Testing Market: Test Type Estimates & Trend Analysis
6.1. Test type Market Share, 2024 & 2033
6.2. Segment Dashboard
6.3. ME Test type Market by Capacity Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
6.5. Predictive Testing
6.5.1. Predictive Testing Market estimates and forecasts 2021 to 2033 (USD Million)
6.6. Diagnostic Testing
6.6.1. Diagnostic Testing Market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 7. ME Hereditary Cancer Testing Market: End Use Estimates & Trend Analysis
7.1. End Use Market Share, 2024 & 2033
7.2. Segment Dashboard
7.3. ME End Use Market by End Use Outlook
7.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
7.5. Diagnostic Centers
7.5.1. Diagnostic Centers Market estimates and forecasts 2021 to 2033 (USD Million)
7.6. Hospitals
7.6.1. Hospitals Market estimates and forecasts 2021 to 2033 (USD Million)
7.7. Clinics
7.7.1. Clinics Market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 8. ME Hereditary Cancer Testing Market: Regional Estimates & Trend Analysis
8.1. Regional Market Share Analysis, 2024 & 2033
8.2. Regional Market Dashboard
8.3. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
8.4. MEA
8.4.1. Saudi Arabia
8.4.1.1. Key country dynamics
8.4.1.2. Regulatory framework/Reimbursement
8.4.1.3. Competitive scenario
8.4.1.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
8.4.2. UAE
8.4.2.1. Key country dynamics
8.4.2.2. Regulatory framework/Reimbursement
8.4.2.3. Competitive scenario
8.4.2.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
8.4.3. Kuwait
8.4.3.1. Key country dynamics
8.4.3.2. Regulatory framework
8.4.3.3. Competitive scenario
8.4.3.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)
8.4.4. Qatar
8.4.4.1. Key country dynamics
8.4.4.2. Regulatory framework/Reimbursement
8.4.4.3. Competitive scenario
8.4.4.4. Qatar market estimates and forecasts 2021 to 2033 (USD Million)
8.4.5. Oman
8.4.5.1. Key country dynamics
8.4.5.2. Regulatory framework/Reimbursement
8.4.5.3. Competitive scenario
8.4.5.4. Oman market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 9. Competitive Landscape
9.1. Recent Developments & Impact Analysis, By Key Market Participants
9.2. Company/Competition Categorization
9.3. Vendor Landscape
9.3.1. List of key distributors and channel partners
9.3.2. Key customers
9.3.3. Key company market share analysis, 2024
9.3.4. Myriad Genetics, Inc.
9.3.4.1. Company overview
9.3.4.2. Financial performance
9.3.4.3. Services benchmarking
9.3.4.4. Strategic initiatives
9.3.5. Invitae Corporation
9.3.5.1. Company overview
9.3.5.2. Financial performance
9.3.5.3. Services benchmarking
9.3.5.4. Strategic initiatives
9.3.6. Bio-Rad Laboratories
9.3.6.1. Company overview
9.3.6.2. Financial performance
9.3.6.3. Services benchmarking
9.3.6.4. Strategic initiatives
9.3.7. CSL Ltd
9.3.7.1. Company overview
9.3.7.2. Financial performance
9.3.7.3. Services benchmarking
9.3.7.4. Strategic initiatives
9.3.8. Qiagen NV
9.3.8.1. Company overview
9.3.8.2. Financial performance
9.3.8.3. Services benchmarking
9.3.8.4. Strategic initiatives
9.3.9. Danaher Corporation
9.3.9.1. Company overview
9.3.9.2. Financial performance
9.3.9.3. Services benchmarking
9.3.9.4. Strategic initiatives
9.3.10. Thermo Fisher Scientific
9.3.10.1. Company overview
9.3.10.2. Financial performance
9.3.10.3. Services benchmarking
9.3.10.4. Strategic initiatives
9.3.11. Abbott Laboratories
9.3.11.1. Company overview
9.3.11.2. Financial performance
9.3.11.3. Services benchmarking
9.3.11.4. Strategic initiatives
9.3.12. EUROFINS SCIENTIFIC
9.3.12.1. Company overview
9.3.12.2. Financial performance
9.3.12.3. Services benchmarking
9.3.12.4. Strategic initiatives
9.3.13. F. HOFFMANN-LA ROCHE LTD
9.3.13.1. Company overview
9.3.13.2. Financial performance
9.3.13.3. Services benchmarking
9.3.13.4. Strategic initiatives
9.3.14. Illumina, Inc.
9.3.14.1. Company overview
9.3.14.2. Financial performance
9.3.14.3. Services benchmarking
9.3.14.4. Strategic initiatives